| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UCRC |
| Uniprot No | Q9UDW1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-63 aa |
| 活性数据 | AAATLTSKLYSLLFRRTSTFALTIIVGVMFFERAFDQGADAIYDHINEGKLWKHIKHKYENK |
| 分子量 | 7.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是假设UCRC为某类重组人蛋白的参考文献示例(因“UCRC”并非标准缩写，可能存在拼写或领域特异性问题，建议核实全称)：
---
1. **文献名称**: *Production and Functional Analysis of Recombinant Human UCRC Protein in E. coli*
**作者**: Zhang L, et al.
**摘要**: 研究报道利用大肠杆菌系统表达重组人UCRC蛋白，优化表达条件后获得高纯度蛋白，并通过体外实验证实其参与线粒体能量代谢调控的功能。
2. **文献名称**: *Structural Characterization of UCRC and Its Role in Cellular Stress Response*
**作者**: Kim S, Park JH.
**摘要**: 通过X射线晶体学解析了重组人UCRC蛋白的三维结构，并发现其在氧化应激条件下调节细胞凋亡通路，为疾病治疗提供潜在靶点。
3. **文献名称**: *UCRC Protein Enhances Drug Delivery Efficiency in Nanocarrier Systems*
**作者**: Wang Y, et al.
**摘要**: 探究重组UCRC蛋白作为药物载体配体的应用，证明其能特异性结合肿瘤细胞表面受体，提升纳米药物的靶向递送效率。
4. **文献名称**: *Clinical Implications of UCRC Overexpression in Neurodegenerative Disorders*
**作者**: Müller R, et al.
**摘要**: 发现阿尔茨海默病患者脑组织中UCRC蛋白表达异常升高，通过重组蛋白模型揭示其与β-淀粉样蛋白沉积的相互作用机制。
---
**注意**：若“UCRC”为特定领域术语(如某研究团队内部命名)，建议结合上下文或补充全称重新检索文献。上述示例为模拟结构，实际文献需通过学术数据库验证。
Recombinant human Ubiquinol-Cytochrome c Reductase Core (UCRC) protein is a key component of mitochondrial complex III (cytochrome bc1 complex), which plays a central role in the electron transport chain (ETC) of oxidative phosphorylation. The UCRC subunit is essential for stabilizing the complex III structure and facilitating electron transfer from ubiquinol to cytochrome c, coupled with proton translocation across the mitochondrial inner membrane to drive ATP synthesis. Dysfunctions in complex III or UCRC are linked to mitochondrial disorders, neurodegenerative diseases, and metabolic syndromes due to impaired energy production and increased oxidative stress.
Recombinant UCRC is produced using genetic engineering techniques, often expressed in bacterial (e.g., *E. coli*) or mammalian systems, enabling high-purity, soluble protein for research. Its production allows detailed studies of mitochondrial ETC mechanisms, protein-protein interactions, and the molecular basis of complex III-associated pathologies. Additionally, recombinant UCRC serves as a critical tool for drug screening, particularly for compounds targeting mitochondrial dysfunction or modulating ROS (reactive oxygen species) generation. Structural and functional analyses using recombinant variants further elucidate mutations impacting enzyme activity and their correlations with clinical phenotypes. Overall, recombinant UCRC is vital for advancing therapeutic strategies and understanding mitochondrial biology in health and disease.
×
